ArticleNature communications2022
A zirconium metal-organic framework with SOC topological net for catalytic peptide bond hydrolysis.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 74 citations in OpenAlex.
- Complete Linker Desymmetrization Enabled Construction of an eft-Topological Zr(IV)-MOF Comprising Two Types of Hexazirconium Nodes for Ammonia Capture.Angewandte Chemie (International ed. in English) · 2026Article
- From Solution to Surface: How the Catalytic Environment Modulates Peptide Bond Cleavage by Metal-Oxo Cluster Nanozymes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanozymes Integrated Biochips Toward Smart Detection System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Hierarchically MOF-Based Porous Monolith Composites for Atmospheric Water Harvesting.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Functionalized metal-organic framework and MOF-derived materials for bone regeneration applications.Frontiers in bioengineering and biotechnology · 2025Review
- Porous Supramolecular Crystalline Probe that Detects Non-Covalent Interactions Involved in Molecular Recognition of Furanic Compounds.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Highly defective ultra-small tetravalent MOF nanocrystals.Nature communications · 2024Article
- Water-stable metal-organic frameworks (MOFs): rational construction and carbon dioxide capture.Chemical science · 2024Review
- Hydrolase mimic via second coordination sphere engineering in metal-organic frameworks for environmental remediation.Nature communications · 2023Article
- A mesoporous Zr-based metal-organic framework driven by the assembly of an octatopic linker.Chemical communications (Cambridge, England) · 2023Article
- Fluorescence immunosensor based on functional nanomaterials and its application in tumor biomarker detection.RSC advances · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of nanozymes for selective fragmentation of proteins would boost the emerging areas of modern proteomics, however, the development of efficient and reusable artificial catalysts for peptide bond hydrolysis is challenging. Here we report the catalytic properties of a zirconium metal-organic framework, MIP-201, in promoting peptide bond hydrolysis in a simple dipeptide, as well as in horse-heart myoglobin (Mb) protein that consists of 153 amino acids. We demonstrate that MIP-201 features excellent catalytic activity and selectivity, good tolerance toward reaction conditions covering a wide range of pH values, and importantly, exceptional recycling ability associated with easy regeneration process. Taking into account the catalytic performance of MIP-201 and its other advantages such as 6-connected Zr
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.